Drug Profile
IGF-paclitaxel conjugate - IGF Oncology
Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator IGF Oncology
- Class Antineoplastics; Diterpenes; Drug conjugates; Paclitaxels; Small molecules; Taxanes
- Mechanism of Action Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 12 Sep 2023 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in USA
- 27 Jul 2016 Preclinical trials in Cancer in USA (unspecified route)